throbber
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ARGENTUM PHARMACEUTICALS LLC,
`
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPR2016—00204
`
`Patent No. RE 38,551
`
`PATENT OWNER’S EXHIBIT LIST
`
`

`
`IPR2016—00204
`
`029819.0100-US03
`
`LIST OF EXHIBITS
`
`Exhibit
`
`Description
`
`2001
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`i2011
`
`2012
`
`L
`
`Richard H. Mattson, Efficacy and Adverse Effects ofEstablished and
`New Antiepileptic Drugs, 36 (Suppl. 2) Epilepsia S13-S26 (1995).
`
`Richard H. Mattson, Drug Treatment of Uncontrolled Seizures, in
`Surgical Treatment of Epilepsy 29-35 (William H. Theodore ed.,
`1992).
`
`FDA Approved Labeling Text dated August 27, 2012 for
`FELBATOL® (felbamate) , available at
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/0201893
`027lbl.pdf (last visited Feb. 2, 2016).
`
`Judith D. Conley & Harold Kohn, Functionalized DL—Amino Acid
`Derivatives. PotentNew Agents for the Treatment ofEpilepsy, 30 J.
`
`(Med. Chem. 567~574 (1987).
`
`U.S. Provisional Patent Application No. 60/013,522.
`
`l
`
`Bialer et al., Progress report on new antiepileptic drugs: a summary
`of the Sixth Eilat Conference (EILAT VI), 51 Epilepsy Res. 31-71
`(2002).
`
`Jerry March, Advanced Organic Chemistry 94-96 (4th ed. 1992).
`
`Decision Denying Institution of Inter Partes Review, IPR2014—
`01126, Paper 22.
`
`Curriculum Vitae of Dr. Farrokh Mistree, September 2014.
`
`Marcy Barge & W.T. Ingram, Inverse Limits on [0,1] Using Logistic
`Bonding Maps, 72 Topology and its Applications 159-72 (1996).
`
`Jack McBryde Jr., Inverse Limits on Arcs Using Certain Logistic
`
`Maps as Bonding Maps, Master’s Thesis, University of Houston,
`(1987).
`
`Trial Testimony of Dr. Clayton Heathcock, UCB, Inc., et al., v.
`Accord Healtheare, Ine., et. al., No. 13-1206-LPS (D. Del., Nov. 9,
`2015).
`
`

`
`IPR2016—00204
`
`I
`
`Exhibit
`_____.._.._______l____.___
`
`Description
`
`029819.0100—US03
`
`2013
`
`2014
`
`2015
`
`2016
`
`2017
`
`FDA Approved Labeling Text dated July 9, 2015 for VIMPAT®
`(lacosamide), available at
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/0222533
`J 030,022254s022,022255s016lb1.pdf (last visited Feb. 2, 2016).
`
`Wolfgang Loscher & Dieter Schmidt, Strategies in Antiepileptic
`Drug Development.‘ Is Rational Drug Design Superior to Random
`Screening and Structural Variation ?, 17 Epilepsy Research 95-134
`(1994).
`
`Michael A. Rogawski & Roger J. Porter, Antiepileptic Drugs:
`Pharmacological Mechanisms and Clinical Efficacy with
`Consideration ofPromising Developmental Stage Compounds, 42(3)
`Pharmacological Reviews 223-86 (1990).
`
`John M. Pellock, Standard Approach to Antiepileptic Drug
`Treatment in the United States 35 (Suppl. 4) Epilepsia S11—S18
`(1994).
`
`Approval Listing dated December 27, 1994 for lamotrigine,
`Approved Drug Products with Therapeutic Equivalence Evaluations
`(Electronic Orange Book),
`http://WWW.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Ap
`pl_No=020241&TABLE1=OB_Rx (last visited Feb. 2, 2016).
`
`2018
`
`The Merck Index 77, 290, 404, 407, 408, 508, 640, 670, 733, 915,
`
`998, 999, 1020, 1028, 1207, 1246, 1247, 1251, 1259, 1260, 1330,
`1654 (Susan Budavari et al. eds., 12th ed. 1996).
`
`2019
`
`2020
`
`Approval Listing dated August 5, 1996 for fosphenytoin sodium,
`Approved Drug Products with Therapeutic Equivalence Evaluations
`(Electronic Orange Book),
`http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfrn?Ap
`pl_No=020450&TABLE1=OB_Rx (last visited Feb. 2, 2016).
`
`FDA Approved Labeling Text dated January 2014 for CEREBYX®
`(fosphenytoin sodium injection) , available at
`http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/0204503
`0231bl.pdf (last visited Feb. 2, 2016).
`
`

`
`IPR2016—00204
`
`029819.0100—US03
`
`Exhibit
`
`
`
`Description
`
`Fl
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`ChemIDPlus, Toxnet, U.S. Nat’l Library of Medicine, Beclamide,
`http://chern.sis.nlm.nih.gov/chemidplus/In/501-68-8 (last Visited Feb.
`2, 2016).
`
`ChemIDPlus, Toxnet, U.S. Nat’l Library of Medicine, Phenacemide,
`http://chem.sis.nlm.nih.gov/chemidplus/rn/63—98—9 (last visited Feb.
`2, 2016).
`
`ChemIDPlus, Toxnet, U.S. Nat’1 Library of Medicine, Valproic acid,
`http://chem.sis.nlm.nih.goV/chemidplus/rn/99-66-1 (last Visited Feb.
`2, 2016).
`
`Portfolio — Mont Alto Capital,
`http://wwwmontaltocapital.com/portfolio/ (last Visited Feb. 23,
`2016).
`
`Trial Transcript, UCB, Inc., et al., v. Accord Healthcare, Inc., et. al.,
`No. 13—1206—LPS (D. Del., Nov. 9-13, 2015). (served, but not filed,
`March 17, 2016)
`
`PTAB Telephonic Conference Transcript, IPR2016—00204 (March 8,
`2016).
`
`PTAB Telephonic Conference Transcript, IPR2016—00204 (April 4,
`2016).
`
`2028
`
`PTAB Email to Counsel of Record (January 12, 2016)
`
`Dated: April 18, 2016
`
`Respectfully submitted,
`
`COVINGTON & BURLING LLP
`
`Andrea G. R ister
`
`
`
`One CityCenter
`850 Tenth Street NW
`
`Washington, DC 20001
`(202) 662-6000
`
`Registration No.: 36,253
`Jennifer L. Robbins
`
`Registration No.: 61,163
`Enrique D. Longton
`Registration No.: 47,304
`Attorneys for Patent Owner
`
`

`
`IPR2016-00204
`
`029819.0100-US03
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 18th day of April
`
`2016, the foregoing Patent ()wner’s Exhibit List and Exhibits 2027-2028 were
`
`served by electronic mail, by agreement of the parties, on the following counsel of
`
`record for Petitioner:
`
`Matthew J. Dowd (MatthewDowd@ar1dreWskurth.com)
`Justin W. Crotty (JustinCrotty@andrewskurth.com)
`Andrews Kurth LLP
`
`1350 I Street, NW, Suite 1100
`
`Washington DC 20005
`
`Dated: April 18, 2016
`
`
`drea G. R/ej ter
`Registration No. 36,252:

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket